References
- Azzam R, Notarianni L, Ali H. Rapid and simple chromatographic method for the determination of diazepam and its major metabolites in human plasma and urine. Journal of Chromatography B: Biomedical Science Applications 1998; 708: 304–309
- Bargetzi M, Aoyama T, Gonzalez F, Meyer U. Lidocaine metabolism in human liver microsome by cytochrome P450IIIA4. Clinical Pharmacology and Therapeutics 1989; 46: 521–527
- Chen Y, Potter J, Ravenscroft J. A quick, sensitive high-performance liquid chromatography assay for monoethylglycinexylidide and lignocaine in serum/plasma using solid-phase extraction. Therapeutic Drug Monitoring 1992; 14: 317–322
- Edwards I. Pharmacological basis of adverse drug reactions. Avery's drug treatment, T Speight, N Holford. Adis International, Auckland 1997; 261–299
- Hindriks F, Groen A. Evaluation of the enzymatic ammonia method for urine on the Du Pont automatic clinical analyzer. Journal of Clinical Chemistry and Clinical Biochemistry 1978; 16: 289–291
- Jemal M, Ouyang Z, Chen B, Teitz D. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Communications in Mass Spectrometry 1999; 13: 1003–1015
- Maezono S, Sugimoto K, Sakamoto K, Ohmori M, Hishikawa S, Mizuta K, Kawarasaki H, Watanabe Y, Fujimura A. Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: Involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein. Pediatric Transplantation 2005; 9: 315–323
- Niwa T, Shiragi T, Yamasaki S, Ishibashi K, Ohno Y, Kagayama A. In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsome. Xenobiotica 2003; 33: 717–729
- Omasa T, Kim K, Hiramatsu S, Katakura Y, Kishimoto M, Enosawa S, Ohtake H. Construction and evaluation of drug-metabolizing cell line for bioartificial liver support system. Biotechnology Progress 2005; 21: 161–167
- Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez F, Satoh T. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996; 26: 1155–1166
- Polasek T, Miners J. In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opinions in Drug Metabolism and Toxicology 2007; 3: 321–329
- Quinn D, Day R. Clinically important drug interactions. Avery's drug treatment, T Speight, N Holford. Adis International, Auckland 1997; 302–337
- Rawden H, Carlile D, Tindal A, Hallifax D, Galetin A, Ito K, Houston J. Microsomal prediction of in vitro clearance and associated interindividual variability of six benzodiazepines in humans. Xenobiotica 2005; 35: 603–625
- Spilker B. Drug development and approval processes. Avery's drug treatment, T Speight, N Holford. Adis International, Auckland 1997; 423–450
- Strobel H, Dignam D. Purification and properties of NADPH-cytochrome P450 reductase. Methods in enzymology, S Fleischer, L Packer. Academic Press, New York, NY 1978; 88–96
- Tang W, Wang R, Lu A. Utility of recombinant cytochrome p450 enzymes: A drug metabolism perspective. Current Drug Metabolism 2005; 6: 503–517
- Wang N, Tsuruoka S, Yamamoto H, Enosawa S, Omasa T, Sata N, Matsumura T, Nagai H, Fujimura A. The bioreactor with CYP3A4- and glutamine synthetase-introduced HepG2 cells: Treatment of hepatic failure dog with diazepam overdosage. Artificial Organs 2005; 29: 681–684
- Yun C, Yim S, Kim D, Ahn T. Functional expression of human cytochrome P450 enzymes in Escherichia coli. Current Drug Metabolism 2006; 7: 411–429
- Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current Drug Metabolism 2008; 9: 310–322